Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Long-Acting Injectable Risperidone in the Treatment of Schizophrenia

30 octobre 2013 mis à jour par: US Department of Veterans Affairs

CSP #555 - Long-Acting Injectable Risperidone in the Treatment of Schizophrenia

In the proposed study 450 veterans with a primary diagnosis of schizophrenia who had at least one psychiatric hospitalization for schizophrenia in the previous 2 years would be randomly assigned at 16 VA medical centers to long-acting injectable risperidone or doctor's choice of oral antipsychotic medication (i.e., excluding other long-acting injectable medications, but not specifying any particular oral agents or dosages). Recruitment would take 27 months to complete, and the study would continue for a third year to allow 9 months of follow-up for the last patient recruited. All patients would be treated from the time of entry up to the end of the three-year study period. Follow-up assessments would continue quarterly. Treatments would not be blinded since giving placebo injections to the comparison group would interfere with the goal of comparing the acceptability of two different methods of medication administration. However, end points will be blindly rated.

Aperçu de l'étude

Description détaillée

The purpose of the study is to assess the effectiveness of long-acting injectable risperidone on psychiatric inpatient hospitalization, schizophrenia symptoms, quality of life, medication adherence, side effects, and health care costs.

Objectives:

Primary: To evaluate the impact of long-acting intramuscular (IM) risperidone on risk of inpatient psychiatric hospitalization in comparison to standard oral antipsychotic treatment in a randomized controlled trial to be conducted with 450 veterans diagnosed with schizophrenia or schizoaffective disorder at 16 VA medical centers over three years.

Secondary: To evaluate adherence, health benefits, and costs of long-acting IM risperidone as compared to standard oral antipsychotic treatment as measured by: a) symptom reduction over 12 months, b) time to all-cause medication discontinuation, c) quality of life, d) VA and non-VA health service use and related costs, e) medication side effects, f) violent behavior, g) use of concomitant medication, and h) the incremental cost-effectiveness ratio.

Type d'étude

Interventionnel

Inscription (Réel)

382

Phase

  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Alabama
      • Tuscaloosa, Alabama, États-Unis, 35404
        • VA Medical Center, Tuscaloosa
    • California
      • Long Beach, California, États-Unis, 90822
        • VA Medical Center, Long Beach
      • Palo Alto, California, États-Unis, 94304-1290
        • VA Palo Alto Health Care System
    • Connecticut
      • West Haven, Connecticut, États-Unis, 06516
        • VA Connecticut Health Care System (West Haven)
    • Florida
      • Miami, Florida, États-Unis, 33125
        • VA Medical Center, Miami
    • Georgia
      • Augusta, Georgia, États-Unis, 30904
        • VA Medical Center, Augusta
    • Illinois
      • Chicago, Illinois, États-Unis, 60612
        • Jesse Brown VAMC (WestSide Division)
    • Massachusetts
      • Boston, Massachusetts, États-Unis, 02130
        • VA Medical Center, Jamaica Plain Campus
    • Michigan
      • Detroit, Michigan, États-Unis, 48201
        • John D. Dingell VA Medical Center, Detroit
    • Minnesota
      • Minneapolis, Minnesota, États-Unis, 55417
        • VA Medical Center, Minneapolis
    • Missouri
      • Kansas City, Missouri, États-Unis, 64128
        • VA Medical Center, Kansas City MO
    • Nebraska
      • Omaha, Nebraska, États-Unis, 68105-1873
        • VA Medical Center, Omaha
    • New Mexico
      • Albuquerque, New Mexico, États-Unis, 87108-5153
        • New Mexico VA Health Care System, Albuquerque
    • New York
      • New York, New York, États-Unis, 10010
        • New York Harbor HCS
    • Ohio
      • Cleveland, Ohio, États-Unis, 44106
        • VA Medical Center, Cleveland
    • Pennsylvania
      • Philadelphia, Pennsylvania, États-Unis, 19104
        • VA Medical Center, Philadelphia
    • Texas
      • Houston, Texas, États-Unis, 77030
        • Michael E. DeBakey VA Medical Center (152)
      • Waco, Texas, États-Unis, 76711
        • Central Texas Veterans Health Care System - Waco
    • Washington
      • Seattle, Washington, États-Unis, 98108
        • VA Puget Sound Health Care System, Seattle

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. Age 18 years or older.
  2. Diagnosed with schizophrenia or schizoaffective disorder by the Structured Clinical Interview for Diagnosis (SCID) (Spitzer and First et al., 1996).
  3. Patients should

    1. have been hospitalized in the two years before study entry on a psychiatric inpatient unit, or
    2. document explicit current evidence of increased use of outpatient services such as additional visits, day treatment or non-hospital residential treatment, increased dosage of medications or addition of concomitant psychotropic medications.

    The b criterion will promptly be adjudicated by the study chairmen on a case-by case basis to insure credibility.

  4. .Adequate transportation is available and the participant lives within a travel time of less than 1.5 hours, allowing attendance at all scheduled visits.
  5. Use of an acceptable method of birth control by female patients who have a possibility of becoming pregnant (safety concerns).
  6. Able to demonstrate decisional capacity in order to give informed consent as assessed by the MacArthur Competence Assessment Tool (MacCAT) (Appelbaum and Grisso, 1996). Guardian consent is acceptable where applicable.
  7. Dually diagnosed patients with both schizophrenia and addictive disorders would be included in this study but should not be in need of acute detoxification for physiologic substance dependence (excluding nicotine) in the past 30 days.

Exclusion Criteria:

  1. Physiologic substance dependence requiring detoxification (excluding nicotine) in the past 30 days (substance abuse is not an exclusion).
  2. Intolerance of risperidone.
  3. Intolerance of intramuscular injection.
  4. Current treatment with depot antipsychotic medication.
  5. Current treatment with oral clozapine or presence of refractory schizophrenia that, in the treating psychiatrist's opinion, requires clozapine.
  6. Hepatic or renal problems AST or ALT (>2 times upper limit of normal);
  7. Elevated bilirubin (>1.2), BUN (>24), creatinine (>1.7).
  8. Unstable, serious medical condition or one requiring acute medical treatment, or anticipation of hospitalization for extended care.
  9. Dementia, epilepsy, insulin-dependent diabetes, anticoagulation with coumadin.
  10. Unstable living arrangements or not planning to remain in the area for the next year.
  11. Legal entanglements or pending legal charges with potential of incarceration.
  12. Assault or suicide gesture currently needing acute intervention.
  13. Concurrent participation in another clinical trial with an investigational drug during the last 30 days.
  14. Pregnant or lactating women or women planning to become pregnant.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Arm 1
long-acting injectable risperidone
long-acting injectable risperidone
Comparateur actif: Arm 2
oral antipsychotic medication
doctor's choice (excluding other long-acting injectable medications but not specifying any particular oral agents or dosages)

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Hospitalization-free Survival - Time to Event
Délai: From randomization until date of first re-hospitalization, assessed up to 24 months
A hospitalization-free survival was defined as the time from the date of randomization to the time of a psychiatric hospitalization (in both VA and non-VA hospitals) or, in the case of patients who were hospitalized at randomization, the time from the date of discharge from the initial stay to subsequent hospitalization. Patients without an event were censored at 24 months after the date of randomization.
From randomization until date of first re-hospitalization, assessed up to 24 months
Hazard Ratio for Hospitalization
Délai: 24 months
Hazard ratio of LAI versus Oral for psychiatric hospitalization (in both VA and non-VA hospitals), after randomization up to 24 months, obtained from a Cox proportional hazards model.
24 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chaise d'étude: Robert A. Rosenheck, AB MD, VA Connecticut Health Care System (West Haven)

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude

1 septembre 2006

Achèvement primaire (Réel)

1 septembre 2009

Achèvement de l'étude (Réel)

1 septembre 2009

Dates d'inscription aux études

Première soumission

17 août 2005

Première soumission répondant aux critères de contrôle qualité

17 août 2005

Première publication (Estimation)

19 août 2005

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Estimation)

20 décembre 2013

Dernière mise à jour soumise répondant aux critères de contrôle qualité

30 octobre 2013

Dernière vérification

1 octobre 2013

Plus d'information

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

Essais cliniques sur IM risperidone

3
S'abonner